Why the study?
Does a home-based disease management program improve psychological status in patients with heart failure?
Does a home-based disease management program improve psychological status in patients with heart failure?
A home-based disease management program significantly improves psychological status and reduces heart failure rehospitalization in patients with heart failure.
Answers are grounded in this paper and cite their sources.
Supports home-based HF disease management; confirms dual psychological and rehospitalization benefits in RCT.
BACKGROUND: A disease management program can reduce mortality and rehospitalization of patients with heart failure (HF), but little is known about whether it can improve psychological status. The purpose of this study was to determine the effects of home-based disease management on the psychological status of patients with HF. METHODS AND RESULTS: We randomly assigned patients hospitalized for HF to undergo either home-based disease management (n=79) or usual care (n=82). The mean age of the study patients was 76 years, 30% were female, and 93% were in NYHA class I or II. Home-based disease management was delivered by nurses via home visit and telephone follow-up to monitor symptoms and body weight and to educate patients. The primary endpoint was psychological status, including depression and anxiety assessed by the Hospital Anxiety and Depression Scale during follow-up of 1 year. Secondary endpoints included quality of life, all-cause death and hospitalization for HF. The intervention group had significantly lower depression (P=0.043) and anxiety (P=0.029) scores than the usual-care group. There were no significant differences in all-cause death [hazard ratio (HR) 1.02, 95% confidence interval (CI) 0.37-2.61, P=0.967]. However, hospitalization for HF was significantly lower in the intervention group than in the usual-care group (HR 0.52, 95% CI 0.27-0.96, P=0.037). CONCLUSIONS: Home-based disease management improved psychological status and also reduced rehospitalization for HF in patients with HF.
No takes yet. Share an insight, caveat, or question.
Tsuchihashi‐Makaya et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: